Study title: Double-Blind, Cross-Over Clinical Study at a Single Centre to Compare Acarbose (BAY g 5421) with Placebo in Respect of Efficacy and Tolerability in Patients with Cystic Fibrosis and Pathological Glucose Tolerance (Pilot Study)(PH-26068)
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Nutritional and Metabolic Diseases [C18] | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: ACARBOSE | |||||
ATC code: A10BF01 | |||||
Document link: Bayer Pharma_Acarbose_0696_study_synopsis.pdf | |||||
Document date: 2011-09-07 | |||||
Study number: BAY-G5421-0696 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | - |